Allergan Plc
About
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
CONTACT DETAILS
Digital content 
NEWS #PharmaBuzz
12 Nov 2025
// PR NEWSWIRE
30 Oct 2025
// INDPHARMAPOST
30 Oct 2025
// PR NEWSWIRE
21 Oct 2025
// PR NEWSWIRE
11 Oct 2025
// INDPHARMAPOST
01 Oct 2025
// PR NEWSWIRE
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 0023-5028
Start Marketing Date : 2024-11-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (200[USP'U]/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 0023-5027
Start Marketing Date : 2024-10-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100[USP'U]/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
Drugs in Development
Lead Product(s) : Onabotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Allergan Launches BOTOX Cosmetic for Masseter Muscle Prominence in China
Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat Masseter Muscle Prominence in adults.
Product Name : Botox Cosmetic
Product Type : Protein
Upfront Cash : Inapplicable
September 11, 2024
Lead Product(s) : TrenibotulinumtoxinE
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Onabotulinumtoxin A,Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Product Name : Botox
Product Type : Protein
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
JUVÉDERM® VOLUX™ XC For Improvement Of Jawline Definition Now Available Nationwide
Details : Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.
Product Name : Juvederm Volux XC
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SkinMedica® Launches Even & Correct
Details : The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.
Product Name : SkinMedica
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Onabotulinumtoxin A,Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
Details : BOTOX (OnabotulinumtoxinA) Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
Product Name : Botox
Product Type : Protein
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Onabotulinumtoxin A,Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign C...
Details : BOTOX® Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Product Name : Botox
Product Type : Protein
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
Details : JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.
Product Name : Juvederm Volux XC
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Onabotulinumtoxin A,Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and ...
Product Name : Botox
Product Type : Protein
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support...
Details : Atogepant (QULIPTA) would be the first gepant (oral calcitonin gene-related peptide [CGRP] receptor antagonist) approved for the broad indication of the preventive treatment of migraine, including episodic and chronic.
Product Name : Qulipta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : CAPSULE
Brand Name : SORIATANE
Dosage Strength : 25MG
Packaging : 30
Approval Date :
Application Number : 2070863
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : CAPSULE
Brand Name : SORIATANE
Dosage Strength : 10MG
Packaging : 30
Approval Date :
Application Number : 2070847
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;SUBLINGUAL
Brand Name : SAPHRIS
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2009-08-13
Application Number : 22117
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;SUBLINGUAL
Brand Name : SAPHRIS
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 2009-08-13
Application Number : 22117
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;SUBLINGUAL
Brand Name : SAPHRIS
Dosage Strength : EQ 2.5MG BASE
Packaging :
Approval Date : 2015-03-12
Application Number : 22117
Regulatory Info : RX
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : FIORINAL
Dosage Strength : 325MG;50MG;40MG **Fede...
Packaging :
Approval Date : 1986-04-16
Application Number : 17534
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Dosage Form : CAPSULE;ORAL
Brand Name : FIORINAL
Dosage Strength : 325MG;50MG;40MG **Fede...
Packaging :
Approval Date : 1986-04-16
Application Number : 17534
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
Dosage Form : CAPSULE;ORAL
Brand Name : FIORINAL W/CODEINE
Dosage Strength : 325MG;50MG;40MG;30MG
Packaging :
Approval Date : 1990-10-26
Application Number : 19429
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Italy
Dosage Form :
Brand Name : Atropine Lux
Dosage Strength : Coll 10 Ml 0.5% ...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Dosage Form :
Brand Name : Atropine Lux
Dosage Strength : Coll 10 Ml 1% ...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Allergan Plc is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Botulinum toxin type A bulk offered by Allergan Plc
Share 
